



**Date: 30/05/2022**

**SUB: OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF CIAN HEALTHCARE LIMITED ("THE COMPANY") HELD ON MAY 30, 2022.**

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to submit the Audited Financials Results for the Half year/Year ended 31<sup>st</sup> March, 2022 which was also approved by the Board of Directors of the Company at their meeting held on **Monday, 30<sup>th</sup> May, 2022 at 5:00 P.M. and concluded at 6:55 P.M.**

Thanking You,  
Yours Faithfully,  
For **CIAN HEALTHCARE LIMITED**

Digitally signed by Munjaji Purbhaji Dhumal  
DN: c=IN, st=Maharashtra,  
2.5.4.20=f052b242ebbdd00c4d9f58eb7b490221ce736c05d6d8596  
7ca43d3bea008520, postalCode=431605,  
street=Satyaji Purbhaji Dhumal,  
pseudoRym=335d029421c24c2540c02d673ab25c736, title=7730,  
serialNumber=97c3f117671312540e48b657eb4795c0f713a6d100f  
9bd4b7918cd4a6173fbf, o=Personal, cn=Munjaji Purbhaji Dhumal  
Date: 2022.05.30 19:07:24 +05'30'

**Encls: Audited Financial Results and Audit Report.**





Independent Auditor's Report on Half Yearly Financial results and year to date results of the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended;

To,  
The Board of Directors of  
Cian Healthcare Limited

## Report on the Audit of the Standalone Financial Statements

### Opinion

We have audited the accompanying standalone financial results of Cian Healthcare Limited (hereinafter referred to as the "Company"), which comprises the Standalone Balance sheet as at 31<sup>st</sup> March 2022, the Standalone Statement of Profit and Loss, the Standalone Statement of Changes in Equity, the Standalone Statement of cash flows as at and for the year ended on that date ("standalone financial results"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results:

- (i) are presented in accordance with the Regulation 33 of the Listing Regulation in this regard; and
- (ii) give a true and fair view in conformity with recognition and measurement principles laid down in the applicable accounting Standards prescribed under section 133 of the Act read with the rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, of the standalone state of affairs of the company as at March 31, 2022, the standalone profit, standalone changes in equity and its standalone cash flows for the year ended on that date.

### Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules



made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

### **Board of Directors Responsibility and those charged with Governance for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the standalone financial position, standalone financial performance, change in equity and Standalone cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### **Going Concern**

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Company's Board of Directors is also responsible for overseeing the company's financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Statements**

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.



As part of an audit in accordance with SAs, We exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Standalone Financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud of higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an undertaking of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(1)(i) of the Act, We are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- d. Conclude on the appropriateness of Management's use of going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events and conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw an attention in our auditor's report to the related disclosures in the Standalone financial statements or if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- f. We communicate with those charged with governance of the Company and such other entities included in the standalone financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that



may reasonably be thought to bear on our independence, and where applicable, related safeguards.

- g. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

#### Other Matters

- a. The standalone financial results include the result for the year ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures upto half year ended 30<sup>th</sup> September 2021 which was subject to limited review by us.
- b. The standalone financial result dealt with by this report has been prepared for the express purpose of filing with stock exchanges on which company's shares are listed. These results are based on and should be read with the audited standalone financial statement of the company for the year ended March 31 2022 on which we issued an unmodified opinion vide our report dated 30<sup>th</sup> May 2022.

For Agarwal Mahesh K. & Co.  
Chartered Accountants

  
CA Ashish Boundia  
Partner

FRN: 008007C

Membership No. 156089

UDIN: - 22156089AJXEWE1846

Place: - Pune

Date: - 30.05.2022



**CIAN HEALTHCARE LTD**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**Company Identification Number : L24233PN2003PLC017563**  
**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR & YEAR ENDED MARCH 31, 2022**

| Particulars                                                                  | (Rs. In Lakhs)   |                      |                                                                 | (Rs. In Lakhs)   |                  |
|------------------------------------------------------------------------------|------------------|----------------------|-----------------------------------------------------------------|------------------|------------------|
|                                                                              | Half Year Ended  |                      |                                                                 | Year Ended       |                  |
|                                                                              | 31st March, 2022 | 30th September, 2021 | Corresponding 6 months ended in previous year on March 31, 2021 | 31st March, 2022 | 31st March, 2021 |
|                                                                              | Audited          | Unaudited            | Audited                                                         | Audited          | Audited          |
| <b>A CONTINUING OPERATIONS</b>                                               |                  |                      |                                                                 |                  |                  |
| 1 Income from operations                                                     | 2,709.74         | 3,700.55             | 3,384.36                                                        | 6,410.29         | 7,238.27         |
| 2 Other income                                                               | 36.22            | 10.84                | 18.30                                                           | 47.06            | 20.30            |
| 3 Total Income (1+2)                                                         | 2,745.97         | 3,711.39             | 3,402.66                                                        | 6,457.35         | 7,258.57         |
| 4 Expenses                                                                   |                  |                      |                                                                 |                  |                  |
| (a) Cost of materials consumed                                               | 1,592.38         | 2,426.30             | 1,867.41                                                        | 4,018.68         | 3,503.18         |
| (b) Purchases of stock-in-trade                                              | 248.69           | 252.74               | 280.06                                                          | 501.42           | 915.71           |
| (c) Changes in inventories of finished goods, work-in-pro                    | -494.25          | -201.55              | -365.72                                                         | -695.80          | -127.74          |
| (d) Other Operating Expenses                                                 | 215.36           | 327.39               | 420.85                                                          | 542.75           | 643.35           |
| (d) Employee benefits expense                                                | 502.71           | 317.75               | 360.35                                                          | 820.46           | 692.88           |
| (e) Finance costs                                                            | 250.33           | 263.54               | 337.70                                                          | 513.87           | 620.96           |
| (f) Depreciation and amortisation expense                                    | 128.52           | 128.28               | 121.85                                                          | 256.80           | 245.15           |
| (g) Other expenses                                                           | 300.33           | 429.57               | 364.43                                                          | 729.90           | 678.52           |
| Total expenses                                                               | 2,744.06         | 3,944.03             | 3,386.92                                                        | 6,688.09         | 7,172.01         |
| 5 Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4) | 1.90             | -232.65              | 15.74                                                           | -230.74          | 86.56            |
| 6 Exceptional items                                                          |                  |                      |                                                                 | -                | -                |
| 7 Profit / (Loss) before extraordinary items and tax (5 ± 6)                 | 1.90             | -232.65              | 15.74                                                           | -230.74          | 86.56            |
| 8 Extraordinary items                                                        | 1.74             | 5.03                 | 6.02                                                            | 6.77             | 20.06            |
| 9 Profit / (Loss) before tax (7 ± 8)                                         | 0.16             | -237.68              | 9.72                                                            | -237.52          | 66.50            |
| 10 Tax expense:                                                              |                  |                      |                                                                 |                  |                  |
| (a) Current tax expense for current year                                     | -                | -                    | 18.12                                                           | -                | 41.18            |
| (b) (Less): MAT credit (where applicable)                                    | -                | -                    | -                                                               | -                | -                |
| (c) Current tax expense relating to prior years                              | -                | -                    | -                                                               | -                | -                |
| (d) Net current tax expense                                                  | -                | -                    | 18.12                                                           | -                | 41.18            |
| (e) Deferred tax                                                             | -9.44            | -0.49                | -4.46                                                           | -9.94            | -7.35            |
|                                                                              | -9.44            | -0.49                | 13.66                                                           | -9.94            | 33.83            |
| 11 Profit / (Loss) from continuing operations (9 ± 10)                       | 9.60             | -237.18              | -3.94                                                           | -227.58          | 32.67            |
| 12 Earnings per share (23360764 Shares of Rs. 10/- each):                    |                  |                      |                                                                 |                  |                  |
| (a) Basic                                                                    |                  |                      |                                                                 |                  |                  |
| (i) Continuing operations                                                    | 0.04             | -1.00                | -0.02                                                           | -0.96            | 0.14             |
| (ii) Total operations                                                        | 0.04             | -1.00                | -0.02                                                           | -0.96            | 0.14             |
| (b) Diluted                                                                  | -                | -                    | -                                                               | -                | -                |
| (i) Continuing operations                                                    | 0.04             | -1.00                | -0.02                                                           | -0.96            | 0.14             |
| (ii) Total operations                                                        | 0.04             | -1.00                | -0.02                                                           | -0.96            | 0.14             |

For and on behalf of Board of Directors  
**CIAN HEALTHCARE LIMITED**  
**CIN:L24233PN2003PLC017563**

Mr. Surej Zanwar  
Managing Director  
DIN: 01304950  
Date: 30/05/2022



**CIAN HEALTHCARE LIMITED**  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

**STATEMENT OF STANDALONE BALANCESHEET AS AT MARCH 31, 2022**

| Particulars |                                                       | Note No. | (Rs. In Lakhs)       | (Rs. In Lakhs)       |
|-------------|-------------------------------------------------------|----------|----------------------|----------------------|
|             |                                                       |          | As at March 31, 2022 | As at March 31, 2021 |
| <b>A</b>    | <b>EQUITY AND LIABILITIES</b>                         |          |                      |                      |
| 1           | Shareholders' funds                                   |          |                      |                      |
|             | (a) Share capital                                     | 3        | 2,499.58             | 2,336.08             |
|             | (b) Reserves and surplus                              | 4        | 3,534.93             | 3,651.36             |
|             | (c) Money received against share warrants             |          |                      |                      |
| 2           | Share application money pending allotment             |          |                      |                      |
| 3           | Non-current liabilities                               |          |                      |                      |
|             | (a) Long-term borrowings                              | 5        | 1,999.24             | 1,837.42             |
|             | (b) Deferred tax liabilities (net)                    | 30.11    | 117.85               | 127.79               |
|             | (c) Other long-term liabilities                       | 6        | 57.30                | 131.25               |
|             | (d) Long-term provisions                              | 7        | 82.49                | 74.51                |
| 4           | Current liabilities                                   |          |                      |                      |
|             | (a) Short-term borrowings                             | 8        | 2,309.22             | 3,122.61             |
|             | (b) Trade payables                                    | 9        | 2,879.30             | 1,770.59             |
|             | (c) Other current liabilities                         | 10       | 465.47               | 345.97               |
|             | (d) Short-term provisions                             | 11       | 32.90                | 65.63                |
|             | <b>TOTAL</b>                                          |          | <b>13,978.28</b>     | <b>13,463.20</b>     |
| <b>B</b>    | <b>ASSETS</b>                                         |          |                      |                      |
| 1           | Non-current assets                                    |          |                      |                      |
|             | (a) Property, Plant and equipment & Intangible Assets |          |                      |                      |
|             | (i) Tangible Assets                                   | 12.A     | 3,282.09             | 1,873.45             |
|             | (ii) Capital work-in-progress                         | 12.B     | 1,299.85             | 2,570.90             |
|             | (iii) Intangible assets under development             |          |                      |                      |
|             | (iv) Fixed assets held for sale                       |          |                      |                      |
|             | (b) Non-current investments                           | 13       | 708.84               | 708.84               |
|             | (c) Deferred tax assets (net)                         | 30.11    |                      |                      |
|             | (d) Long-term loans and advances                      | 14       | 1,410.29             | 1,995.09             |
|             | (e) Other non-current assets                          | 15       | 397.92               | 547.84               |
| 2           | Current assets                                        |          |                      |                      |
|             | (a) Current investments                               | 16       | -                    | -                    |
|             | (b) Inventories                                       | 17       | 3,401.69             | 2,570.93             |
|             | (c) Trade receivables                                 | 18       | 1,826.05             | 1,853.59             |
|             | (d) Cash and cash equivalents                         | 19       | 122.27               | 220.95               |
|             | (e) Short-term loans and advances                     | 20       | 451.89               | 415.79               |
|             | (f) Other current assets                              | 21       | 1,077.39             | 705.81               |
|             | <b>TOTAL</b>                                          |          | <b>13,978.28</b>     | <b>13,463.20</b>     |

For and on behalf of Board of Directors  
Cian Healthcare Limited  
CIN:L24233PN2003PLC017563

Mr. Suraj Zolotar  
Managing Director  
DIN: 01304850

Place : Pune  
Date: 30/05/2022



**CIAN HEALTHCARE LIMITED**  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

**STATEMENT OF STANDALONE CASHFLOW AS AT MARCH 31, 2022**

| Particulars                                                               | As at March 31,<br>2022 | As at March 31,<br>2021 |
|---------------------------------------------------------------------------|-------------------------|-------------------------|
| <b>Cash Flow from operating activities</b>                                |                         |                         |
| Net Profit after tax                                                      | -227.58                 | 32.67                   |
| Adjustment for:                                                           |                         |                         |
| - Depreciation and amortization expense                                   | 256.80                  | 245.15                  |
| - Depreciation reserve written off                                        | -3.29                   | -                       |
| - (Profit) / Loss on Sale/Disposal of assets                              |                         |                         |
| - Interest Expenses                                                       | 476.14                  | 583.70                  |
| - Interest & Dividend received                                            | -9.85                   | -11.55                  |
| - Deferred Tax Liability                                                  | -9.94                   | -7.35                   |
| <b>Operating profit before working capital changes</b>                    | <b>482.28</b>           | <b>842.62</b>           |
| (Increase) / Decrease in Other Non Current asset                          | 149.92                  | 244.05                  |
| (Increase) / Decrease in Inventories                                      | -830.76                 | -599.30                 |
| (Increase) / Decrease in Trade receivables                                | 27.54                   | 141.02                  |
| (Increase) / Decrease in Other Current Assets                             | -371.58                 | -267.30                 |
| (Increase) / Decrease in Deferred Tax Asset                               |                         |                         |
| (Increase) / Decrease in other financial assets                           | -36.10                  | 32.72                   |
| Increase / (Decrease) in Provisions                                       | -24.75                  | 37.89                   |
| Increase / (Decrease) in Trade Payables                                   | 1,108.71                | 172.01                  |
| Increase / (Decrease) in Other Financial Liabilities/Short Term Borrowing |                         |                         |
| Increase / (Decrease) in Deferred tax liabilities                         | -                       |                         |
| Increase / (Decrease) in Other Current Liabilities                        | 119.51                  | -91.28                  |
| Increase / (Decrease) in Other Non Current Liabilities                    | -73.96                  | 33.70                   |
| <b>Cash generated from operations</b>                                     | <b>550.81</b>           | <b>546.13</b>           |
| Taxes paid                                                                |                         |                         |
| <b>Net cash from operating activities</b>                                 | <b>550.81</b>           | <b>546.13</b>           |
| <b>Cash flow from Investing activities</b>                                |                         |                         |
| Purchase of fixed assets                                                  | -1,665.43               | -41.08                  |
| Proceeds from sale of fixed assets/Subsidy                                | 0                       | -                       |
| (Increase) / Decrease in Capital Work in Progress                         | 1,271.05                | -90.73                  |
| Interest & Dividend received                                              | 9.85                    | 11.55                   |
| Purchases of Shares of Dr. Smiths Biotech Private Ltd.                    |                         |                         |
| Proceeds / (Repayment) of Other Financial Assets/Long Term Liabilities    |                         |                         |
| <b>Net Cash flow from investing activities</b>                            | <b>-384.53</b>          | <b>-120.26</b>          |
| <b>Cash flow from financing activities</b>                                |                         |                         |
| Proceeds from issuance of Share Capital including share premium           | 277.95                  | -                       |
| Proceeds from long term borrowings                                        | 161.82                  | -611.62                 |
| Proceeds / (Repayment) from / of short term borrowings (Above)            | -813.39                 | 428.42                  |
| Proceeds from Share Application Money                                     |                         |                         |
| Dividend Paid including dividend distribution tax                         |                         |                         |
| Proceeds / (Repayment) for Other Financial Assets                         | 584.80                  | 260.14                  |
| Interest paid                                                             | -476.14                 | -583.70                 |
| <b>Net Cash flow from Financing Activities</b>                            | <b>-264.96</b>          | <b>-506.77</b>          |
| <b>Increase / (Decrease) in cash and cash equivalents</b>                 | <b>-98.68</b>           | <b>-80.90</b>           |
| Cash and cash equivalents at beginning of the year                        | 220.95                  | 301.85                  |
| <b>Cash and cash equivalents at end of the year</b>                       | <b>122.27</b>           | <b>220.95</b>           |

For and on behalf of Board of Directors  
Cian Healthcare Limited  
CIN:L24233PN2003PLC017563

Mr. Suraj Zanwar  
Managing Director  
DIN: 01204850

Place : Pune  
Date: 30/05/2022




**Notes:**

1. The Above Financial Results and Statement of Assets and Liabilities were prepared as per Accounting Standards and reviewed by the audit committee and then approved by the Board of Directors at their respective meetings held on 30th May, 2022
2. The Results for the half year and Year ended on 31st March, 2022 are audited by the Statutory Auditors of the company in compliance with the regulation 33 of SEBI (LODR) Regulations, 2015
3. The Earning Per Share (EPS) has been computed in accordance with the AS-20
4. List of Subsidiary as on 31st March, 2022  
Name of the Entity : Dr. Smiths Biotech Private Limited  
Relationship : Subsidiary  
Country of Incorporation : India  
% of Ownership : 100%
5. Other Income for the year ended on 31.03.2022 includes Interest on Fixed Deposites, Income from Export benefits & Other Misc. Income and Realized and Unrealized Foreign Exchange Gain/ (Loss)
6. The Status of Investors Complaints during the half year ended on 31.03.2022 is as under  
Pending at the beginning of the above period: NIL  
Received during the above period: NIL  
Disposed during the above period: NIL  
Remaining unsolved at the end of the above period: NIL
7. Figures of previous year/Period have been regrouped/recasted wherever necessary, in order to make them comparable.
8. The company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the half year/ year ended 31.03.2022 hence no separate separate segment reporting is given as per AS-17
9. As per MCA Notification dated 16.02.2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital disclosure Requirements) Regulations, 2009 are Exempted from the compulsory requirement of Adoption of IND-AS. Hence company has prepared its financials as per Accounting Standards

**For and on behalf of Board of Directors**

**CIAN HEALTHCARE LIMITED**

**CIN:L24233PN2003PLC017563**

  
**Mr. Suraj Zanwar**  
**Managing Director**  
**DIN: 01304850**  
**Date: 30/05/2022**





Independent Auditor's Report on Half Yearly Financial results and year to date results of the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended;

To,  
The Board of Directors of  
Cian Healthcare Limited

### Report on the Audit of the Consolidated Financial Statements

#### Opinion

We have audited the accompanying consolidated financial results of Cian Healthcare Limited (hereinafter referred to as the "Holding Company") and its subsidiary (the Parent & Subsidiary referred to as the "Group"), which comprises the Consolidated Balance sheet as at 31<sup>st</sup> March 2022, the Consolidated Statement of Profit and Loss, the Consolidated Statement of Changes in Equity, the Consolidated Statement of cash flows as at and for the year ended on that date ("consolidated financial results"), attached herewith, being submitted by the Holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial results:

- (i) Include the annual financial results of the following entities:

#### Holding Company

- Cian Healthcare Limited

#### Subsidiary Company

- Dr. Smiths Biotech Private Limited

- (ii) Is presented in accordance with the Regulation 33 of the Listing Regulation in this regard; and
- (iii) give a true and fair view in conformity with recognition and measurement principles laid down in the applicable accounting Standards prescribed under section 133 of the Act read with rule 7 of Companies (Accounts) Rules, 2014, and other accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at March 31, 2022, the consolidated profit, consolidated changes in equity and its consolidated cash flows for the year ended on that date.



## **Basis for Opinion**

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and other auditor in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

## **Board of Directors Responsibility and those charged with Governance for the Consolidated Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance, change in equity and Consolidated cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

## **Going Concern**

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.



Company's Board of Directors is also responsible for overseeing the company's financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Consolidated Financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an undertaking of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(1)(i) of the Act, We are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- d. Conclude on the appropriateness of Management's use of going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events and conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated financial statements or if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However future events or conditions may cause the Company to cease to continue as a going concern.



- e. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- f. Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entity included in the consolidated financial results, which has been audited by other auditor, such other auditor remains responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
- g. We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
- h. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

#### Other Matters

- a. The consolidated financial result includes audited financial results of one subsidiary named Dr.Smiths Biotech Private Limited, whose financial statement reflects total asset of Rs.3452.98 lakhs as at 31<sup>st</sup> March 2022, total income of Rs.1617.42 lakhs for the year ended 31<sup>st</sup> March 2022, total net loss after tax is Rs.325.77 lakhs for the year ended on that date. The financial statement of subsidiary has been audited by other auditor whose reports have been furnished to us by the management and our opinion and conclusion on the statement, in so far as it relates to the amounts and disclosure included in respect of the subsidiary, is based solely on the reports of the other auditor and the procedure performed by us as stated under Auditor's responsibility section above.



Our opinion on the consolidated financial results is not modified in respect of the above matter with respect to our reliance on the work done and the report of other auditor.

- b. The consolidated financial results also includes the Group's share of profit/loss after tax of (Rs. 168.16 Lakhs) and (Rs. 553.35 Lakhs) for the half year ended 30<sup>th</sup> September 2021 and year ended 31<sup>st</sup> March 2022 respectively, as considered in the statement.
- c. The consolidated financial results include the result for the half year ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures upto half year ended 30<sup>th</sup> September 2021 which was subject to limited review by us.
- d. The consolidated financial result dealt with by this report has been prepared for the express purpose of filing with stock exchanges on which company's shares are listed. These results are based on and should be read with the audited consolidated financial statement of the company for the year ended March 31 2022 on which we issued an unmodified opinion vide our report dated 30<sup>th</sup> May 2022.

For Agarwal Mahesh K. & Co.  
Chartered Accountants

  
CA Ashish Boundia  
Partner



FRN: 008007C

Membership No. 156089

UDIN: - 22156089AJXFLJ9699

Place: - Pune

Date: - 30.05.2022

**CIAN HEALTHCARE LTD**  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
Company Identification Number : L24233PN2003PLC017563

**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR & YEAR ENDED MARCH 31, 2022**

| Particulars                                                                  | (Rs. in Lakhs)   |                      |                                                                 | (Rs. in Lakhs)   |                  |
|------------------------------------------------------------------------------|------------------|----------------------|-----------------------------------------------------------------|------------------|------------------|
|                                                                              | Half Year Ended  |                      |                                                                 | Year Ended       |                  |
|                                                                              | 31st March, 2022 | 30th September, 2021 | Corresponding 6 months ended in previous year on March 31, 2021 | 31st March, 2022 | 31st March, 2021 |
|                                                                              | Audited          | Unaudited            | Audited                                                         | Audited          | Audited          |
| <b>A CONTINUING OPERATIONS</b>                                               |                  |                      |                                                                 |                  |                  |
| 1 Income from operations                                                     | 3,095.86         | 4,691.18             | 3,483.54                                                        | 7,787.03         | 7,373.01         |
| 2 Other income                                                               | 37.09            | 16.54                | 18.79                                                           | 53.62            | 28.04            |
| 3 Total Income (1+2)                                                         | 3,132.95         | 4,707.71             | 3,502.32                                                        | 7,840.66         | 7,401.05         |
| 4 Expenses                                                                   |                  |                      |                                                                 |                  |                  |
| (a) Cost of materials consumed                                               | 2,030.77         | 2,935.34             | 1,798.90                                                        | 4,966.12         | 3,436.73         |
| (b) Purchases of stock-in-trade                                              | 248.69           | 263.76               | 318.07                                                          | 512.44           | 965.04           |
| (c) Changes in inventories of finished goods, work-in-progress               | -561.32          | -126.62              | -586.26                                                         | -687.94          | -354.98          |
| (d) Other Operating Expenses                                                 | 324.47           | 432.49               | 493.95                                                          | 756.96           | 716.45           |
| (d) Employee benefits expense                                                | 613.71           | 371.88               | 382.74                                                          | 985.59           | 716.30           |
| (e) Finance costs                                                            | 320.39           | 323.76               | 416.13                                                          | 644.15           | 772.27           |
| (f) Depreciation and amortisation expense                                    | 248.14           | 179.35               | 121.59                                                          | 427.49           | 345.27           |
| (g) Other expenses                                                           | 348.69           | 480.13               | 394.43                                                          | 828.82           | 714.24           |
| Total expenses                                                               | 3,573.53         | 4,860.11             | 3,339.55                                                        | 8,433.64         | 7,311.34         |
| 5 Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4) | -440.59          | -152.40              | 162.77                                                          | -592.98          | 89.71            |
| 6 Exceptional items                                                          |                  |                      |                                                                 |                  |                  |
| 7 Profit / (Loss) before extraordinary items and tax (5 ± 6)                 | -440.59          | -152.40              | 162.77                                                          | -592.98          | 89.71            |
| 8 Extraordinary items                                                        | 2.30             | 5.04                 | 6.47                                                            | 7.33             | 21.01            |
| 9 Profit / (Loss) before tax (7 ± 8)                                         | -442.88          | -157.43              | 156.31                                                          | -600.32          | 68.70            |
| 10 Tax expense:                                                              |                  |                      |                                                                 |                  |                  |
| (a) Current tax expense for current year                                     | -                | -                    | 18.12                                                           | -                | 41.18            |
| (b) (Less): MAT credit (where applicable)                                    | -                | -                    | -                                                               | -                | -                |
| (c) Current tax expense relating to prior years                              | -                | -                    | -                                                               | -                | -                |
| (d) Net current tax expense                                                  | -                | -                    | 18.12                                                           | -                | 41.18            |
| (e) Deferred tax                                                             | -57.68           | 10.72                | 25.11                                                           | -46.96           | 22.22            |
|                                                                              | -57.68           | 10.72                | 43.23                                                           | -46.96           | 63.39            |
| 11 Profit / (Loss) from continuing operations (9 ± 10)                       | -385.20          | -168.16              | 113.08                                                          | -553.35          | 5.31             |
| 12 Earnings per share (24995764 Shares of Rs. 10/- each):                    |                  |                      |                                                                 |                  |                  |
| (a) Basic                                                                    | -1.62            | -0.71                | 0.48                                                            | -2.32            | 0.02             |
| (i) Continuing operations                                                    | -1.62            | -0.71                | 0.48                                                            | -2.32            | 0.02             |
| (ii) Total operations                                                        | -1.62            | -0.71                | 0.48                                                            | -2.32            | 0.02             |
| (b) Diluted                                                                  | -1.62            | -0.71                | 0.48                                                            | -2.32            | 0.02             |
| (i) Continuing operations                                                    | -1.62            | -0.71                | 0.48                                                            | -2.32            | 0.02             |
| (ii) Total operations                                                        | -1.62            | -0.71                | 0.48                                                            | -2.32            | 0.02             |

For and on behalf of Board of Directors  
CIAN HEALTHCARE LIMITED  
CIN:L24233PN2003PLC017563

Mr. Suraj Zanwar  
Managing Director  
DIN: 04304850  
Date: 30/05/2022



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF CONSOLIDATED BALANCESHEET AS AT MARCH 31, 2022**

| Particulars |                                                       | Note No. | As at March 31,<br>2022 | As at March 31,<br>2021 |
|-------------|-------------------------------------------------------|----------|-------------------------|-------------------------|
| <b>A</b>    | <b>EQUITY AND LIABILITIES</b>                         |          |                         |                         |
| 1           | Shareholders' funds                                   |          |                         |                         |
|             | (a) Share capital                                     | 3        | 2,499.58                | 2,336.08                |
|             | (b) Reserves and surplus                              | 4        | 3,046.11                | 3,488.31                |
|             | (c) Money received against share warrants             |          |                         |                         |
| 2           | Share application money pending allotment             |          |                         |                         |
| 3           | Non-current liabilities                               |          |                         |                         |
|             | (a) Long-term borrowings                              | 5        | 3,813.13                | 3,764.05                |
|             | (b) Deferred tax liabilities (net)                    | 29       | 149.63                  | 196.59                  |
|             | (c) Other long-term liabilities                       | 6        | 57.30                   | 86.68                   |
|             | (d) Long-term provisions                              | 7        | 82.49                   | 74.51                   |
| 4           | Current liabilities                                   |          |                         |                         |
|             | (a) Short-term borrowings                             | 8        | 2,491.74                | 3,309.05                |
|             | (b) Trade payables                                    | 9        | 3,549.70                | 2,057.28                |
|             | (c) Other current liabilities                         | 10       | 855.77                  | 329.98                  |
|             | (d) Short-term provisions                             | 11       | 48.07                   | 82.63                   |
|             | <b>TOTAL</b>                                          |          | <b>16,593.51</b>        | <b>15,725.16</b>        |
| <b>B</b>    | <b>ASSETS</b>                                         |          |                         |                         |
| 1           | Non-current assets                                    |          |                         |                         |
|             | (a) Property, Plant and equipment & Intangible Assets |          |                         |                         |
|             | (i) Tangible Assets                                   | 12.A     | 4,957.91                | 3,653.62                |
|             | (iii) Capital work-in-progress                        | 12.B     | 1,299.85                | 2,593.42                |
|             | (iv) Intangible assets under development              |          |                         |                         |
|             | (v) Fixed assets held for sale                        |          |                         |                         |
|             | (b) Non-current investments                           | 13       | 488.84                  | 488.84                  |
|             | (c) Deferred tax assets (net)                         | 29       |                         |                         |
|             | (d) Long-term loans and advances                      | 14       | 1,443.14                | 2,004.86                |
|             | (e) Other non-current assets                          | 15       | 507.93                  | 647.84                  |
| 2           | Current assets                                        |          |                         |                         |
|             | (a) Current investments                               | 16       |                         |                         |
|             | (b) Inventories                                       | 17       | 3,937.16                | 3,072.51                |
|             | (c) Trade receivables                                 | 18       | 2,672.13                | 1,889.97                |
|             | (d) Cash and cash equivalents                         | 19       | 134.15                  | 232.47                  |
|             | (e) Short-term loans and advances                     | 20       | 755.13                  | 682.69                  |
|             | (f) Other current assets                              | 21       | 397.27                  | 458.93                  |
|             | <b>TOTAL</b>                                          |          | <b>16,593.51</b>        | <b>15,725.16</b>        |

For and on behalf of Board of Directors  
Cian Healthcare Limited  
CIN:L24233PN2003PLC017563

Mr. Suraj Zambhar  
Managing Director  
DIN: 01304880

Place : Pune  
Date : 30/05/2022



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF CONSOLIDATED CASHFLOW AS AT MARCH 31, 2022**

| Particulars                                                                | As at March 31,<br>2022 | As at March 31,<br>2021 |
|----------------------------------------------------------------------------|-------------------------|-------------------------|
| <b>Cash Flow from operating activities</b>                                 |                         |                         |
| Net Profit after tax                                                       | -553.35                 | 5.31                    |
| Adjustment for:                                                            |                         |                         |
| - Depreciation and amortization expense                                    | 427.49                  | 345.27                  |
| - Depreciation reserve written off                                         | -3.29                   |                         |
| - (Profit) / Loss on Sale/Disposal of assets                               |                         |                         |
| - Interest Expenses                                                        | 605.40                  | 734.98                  |
| - Interest & Dividend received                                             | -16.06                  | -19.29                  |
| - Deferred Tax Liability                                                   | -46.96                  | 22.22                   |
| <b>Operating profit before working capital changes</b>                     | <b>413.23</b>           | <b>1,088.49</b>         |
| (Increase) / Decrease in Other Non Current asset                           | 139.91                  | 244.05                  |
| (Increase) / Decrease in Inventories                                       | -864.66                 | -1,100.88               |
| (Increase) / Decrease in Trade receivables                                 | -782.16                 | 108.59                  |
| (Increase) / Decrease in Other Current Assets                              | 61.67                   | -20.42                  |
| (Increase) / Decrease in Deferred Tax Asset                                |                         |                         |
| (Increase) / Decrease in other financial assets                            | -72.44                  | -12.78                  |
| Increase / (Decrease) in Provisions                                        | -26.59                  | 41.21                   |
| Increase / (Decrease) in Trade Payables                                    | 1,492.42                | 433.14                  |
| Increase / (Decrease) in Other Financial Liabilities/Long Term Liabilities | -29.38                  | -79.78                  |
| Increase / (Decrease) in Deferred tax liabilities                          |                         |                         |
| Increase / (Decrease) in Other Current Liabilities                         | 525.79                  | -108.35                 |
| Increase / (Decrease) in Other Non Current Liabilities                     |                         |                         |
| <b>Cash generated from operations</b>                                      | <b>857.78</b>           | <b>593.28</b>           |
| Taxes paid                                                                 |                         |                         |
| <b>Net cash from operating activities</b>                                  | <b>857.78</b>           | <b>593.28</b>           |
| <b>Cash flow from Investing activities</b>                                 |                         |                         |
| Purchase of fixed assets                                                   | -1,731.77               | -56.29                  |
| Proceeds from sale of fixed assets/Subsidy                                 |                         |                         |
| (Increase) / Decrease in Capital Work in Progress                          | 1,293.57                | -90.83                  |
| Interest & Dividend received                                               | 16.06                   | 19.29                   |
| Purchases of Shares of Dr. Smiths Biotech Private Ltd.                     |                         |                         |
| Proceeds / (Repayment) of Other Financial Assets/Long Term Liabilities     | 561.72                  | 399.19                  |
| <b>Net Cash flow from investing activities</b>                             | <b>139.58</b>           | <b>271.35</b>           |
| <b>Cash flow from financing activities</b>                                 |                         |                         |
| Proceeds from issuance of Share Capital including share premium            | 277.95                  |                         |
| Proceeds from long term borrowings                                         | 49.08                   | -819.71                 |
| Proceeds / (Repayment) from / of short term borrowings (Above)             | -817.31                 | 577.19                  |
| Proceeds from Share Application Money                                      |                         |                         |
| Dividend Paid including dividend distribution tax                          |                         |                         |
| Proceeds / (Repayment) for Other Financial Assets                          |                         |                         |
| Interest paid                                                              | -605.40                 | -734.98                 |
| <b>Net Cash flow from Financing Activities</b>                             | <b>-1,095.68</b>        | <b>-977.50</b>          |
| <b>Increase / (Decrease) in cash and cash equivalents</b>                  | <b>-98.32</b>           | <b>-112.88</b>          |
| Cash and cash equivalents at beginning of the year                         | 232.47                  | 345.35                  |
| <b>Cash and cash equivalents at end of the year</b>                        | <b>134.15</b>           | <b>232.47</b>           |

For and on behalf of Board of Directors

Cian Healthcare Limited

CIN:L24233PN2003PLC017563


Mr. Suraj Zanwar

Managing Director

DIN: 01304859

Place : Pune

Date : 30/05/2022



**Notes:**

1. The Above Financial Results and Statement of Assets and Liabilities were prepared as per Accounting Standards and reviewed by the audit committee and then approved by the Board of Directors at their respective meetings held on 30th May, 2022
2. The Results for the half year and Year ended on 31st March, 2022 are audited by the Statutory Auditors of the company in compliance with the regulation 33 of SEBI (LODR) Regulations, 2015
3. The Earning Per Share (EPS) has been computed in accordance with the AS-20
4. The consolidated accounts have been prepared as per AS-21
5. List of Subsidiary as on 31st March, 2022  
Name of the Entity : Dr. Smiths Biotech Private Limited  
Relationship : Subsidiary  
Country of Incorporation : India  
% of Ownership : 100%
6. Other Income for the year ended on 31.03.2022 includes Interest on Fixed Deposites, Income from Export benefits & Other Misc. Income and Realized and Unrealized Foreign Exchange Gain/ (Loss)
7. The Status of Investors Complaints during the half year ended on 31.03.2022 is as under  
Pending at the beginning of the above period: NIL  
Received during the above period: NIL  
Disposed during the above period: NIL  
Remaining unsolved at the end of the above period: NIL
8. Figures of previous year/Period have been regrouped/recasted wherever necessary, in order to make them comparable.
9. The company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the half year/ year ended 31.03.2022 hence no separate separate segment reporting is given as per AS-17
10. As per MCA Notification dated 16.02.2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital disclosure Requirements) Regulations, 2009 are Exempted from the compulsory requirement of Adoption of IND-AS. Hence company has prepared its financials as per Accounting Standards

**For and on behalf of Board of Directors**  
**CIAN HEALTHCARE LIMITED**  
**CIN:L24233PN2003PLC017563**

  
**Mr. Suraj Zangwar**  
**Managing Director**  
**DIN: 01304850**





Date: - 30.05.2022

To  
Board of Directors  
Cian Healthcare Limited  
Pune

Dear Sirs,

**Sub: - Declaration pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015 as amended**

**DECLARATION**

It is hereby declared that we, Agarwal Mahesh K & Co., Chartered Accountants, have issued Audit Reports on Standalone and Consolidated audited financial results of the company for the Financial Year ended March 31, 2022 with unmodified opinion.

Kindly take the same on your record.

Warm Regards,

For Agarwal Mahesh K. & Co.  
Chartered Accountants

  
CA Ashish Boundia  
Partner



FRN No. - 008007C

M.No. - 156089

UDIN: 22156089AJXFLJ9699

Pune

**Corporate Office:**

Office No. 508-511, Sacred World, 5<sup>th</sup> Floor, Above Macdonald,  
Vithal Rao Shivarkar Road, Wanowrie, Pune - 411040  
Email: enquiry@cian.co, cianhealthcare@yahoo.co.in  
Web: www.cian.co

**Registered Office:**

Milkar No. 16431, Block No. 1 from South Side, C.S. No. 227/10 3B,  
Harpale Park, Opp. Berger Paint, Phursungi, Tal. Haveli, Dist. Pune - 412 308,  
(Maharashtra) INDIA. Tele-Fax: +91-20-26982792

**Factory:**

Kh. No. 248, Village Sisona, Bhagwanpur, Roorkee, Haridwar,  
Pin - 247 661, Uttarakhand, Tel.: 1332 235352

CIN: L24233PN2003PLC017563


Date: 30/05/2022

**CEO & CFO Certificate under Regulation 33(2) (a) of SEBI (LODR) Regulation, 2015**

To,  
The Board of Directors of  
Cian Healthcare Limited

- A. We have reviewed financial statements and cash flow statement of Cian Healthcare Limited for the Year ended on 31<sup>st</sup> March, 2022 and to the best of our knowledge and belief:
- (1) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
  - (2) These statements together present a true and fair view of the listed entity affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. There are to the best of our knowledge and belief no transactions entered into by the listed entity. During the year ended 31.03.2022 which is fraudulent, illegal or violative of Company's Code of Conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and we have evaluated the effectiveness of internal control systems of the Company pertaining to Financial Reporting and they have disclosed to the Auditor's and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which we are aware and the steps we have taken or proposes to take to rectify, these deficiencies.
- D. We have indicated to the Auditors and the Audit Committee:
- (i) That there are no significant changes in internal control over financial reporting during the year;
  - (ii) That there are no significant changes in accounting policies during the year; subject to changes in the Same and that the same have been disclosed in the Notes to the Financial Statement and
  - (iii) That there are no instances of significant fraud of which we become aware and the involvement there in, if any, of the Management or an employee having significant role in the company's internal control system over Financial Reporting.

  
**Mr. SURAJ SHRINIVAS ZANWAR**  
Managing Director  
(DIN: 01304850)



  
**Mr. RIYAZ BASHIR KHAN**  
Chief Financial Officer  
(DIN: 07578366)



**CIAN HEALTHCARE LIMITED**

**(An ISO 9001:2015 & WHO GMP Certified Co.)**

**Corporate Office:**

Office No. 508-511, Sacred World, 5<sup>th</sup> Floor, Above Macdonald,  
Vithal Rao Shivarkar Road, Wanowrie, Pune – 411040  
Email: enquiry@cian.co, cianhealthcare@yahoo.co.in  
Web: www.cian.co

**Registered Office:**

Milkat No. 16431, Block No. 1 from South Side, C.S. No. 227/10 3B,  
Harpale Park, Opp. Berger Paint, Phursungi, Tal. Havell, Dist. Pune - 412 308,  
(Maharashtra) INDIA. Tele-Fax.: +91-20-26982792

**Factory:**

Kh. No.: 248, Village Sisona, Bhagwanpur, Roorkee, Haridwar,  
Pin - 247 661. Uttarakhand, Tel.: 1332 235352

CIN: L24233PN2003PLC017563

**Date: 30/05/2022**

To,  
BSE Limited – CRD  
P.J. Towers, Dalal Street,  
Fort, Mumbai-400001

**Script Code: 542678**

**Subject: Declaration on Audited Financial Result in compliance with the Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir(s),


Pursuant to second proviso to the Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We, the Board of Directors of Cian Healthcare Limited, hereby declare that the Statutory Auditor of the Company, M/s. Agarwal Mahesh K. & Co, Chartered Accountant (FRN: 008007C) has issued the Audit Report with unmodified opinion on the Standalone and Consolidated Audited Financial Results of the Company for the half year and year ended 31<sup>st</sup> March, 2022.

Request you to please take the above details on record.

Thanking You,

Yours Faithfully,

For CIAN HEALTHCARE LIMITED

  
SURAJ SHRINIWAS ZANWAR  
MANAGING DIRECTOR  
DIN: 01304850

